(Roche) Oct 15, 2018 - Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment. Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency. Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December.
Read full article.

(Business Insider) Oct 12, 2018 - Google is developing a tool to help doctors diagnose breast cancer using artificial intelligence. The tool, known as LYmph Node Assistant, or LYNA, could one day act as a sort of "spell check" for pathologists, the doctors responsible for diagnosing cancer patients through images of their cells. In two papers published Friday, Google found that its algorithm complemented what the pathologists were able to pick up from the images in terms of determining how much patients' cancers had spread in their lymph node tissue. "This represents a demonstration that people can work really well with AI algorithms than either one alone," Yun Liu, a member of the Google AI team and an author on the papers, told Business Insider.
Read full article.

Sloan Kettering Researchers Correct the Record by Revealing Company Ties

Read full article.